ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
45 authors at 20 institutions in 9 countries.
Claire E Thomas *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-9515-3277
Peter Georgeson *Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.ORCID 0000-0002-5096-4735
Conghui Qu *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-1927-6245
Robert S SteinfelderPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-4204-8013
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.ORCID 0000-0003-2225-6675
Mingyang SongDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.ORCID 0000-0002-1324-0316
Tabitha A HarrisonPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-4173-7530
Caroline Y UmDepartment of Population Science, American Cancer Society, Atlanta, Georgia.ORCID 0000-0001-5449-6230
Meredith A HullarPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-5322-9568
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.ORCID 0000-0002-8964-6160
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X
Brigid M LynchCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.ORCID 0000-0001-8060-547X
Yohannes Adama MelakuCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0002-3051-7313
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-6027-9806
Elom K AglagoDepartment of Epidemiology and Biostatistics, Imperial College London, School of Public Health, London, UK.ORCID 0000-0002-0442-3284
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-5230-0652
Lisa A BoardmanGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1330-2054
Peter T CampbellDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.ORCID 0000-0002-5549-2036
Yin CaoDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0001-9835-7662
Andrew T ChanDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.ORCID 0000-0001-7284-6767
David A DrewClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8813-0816
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8040-3341
Amy J FrenchDivision of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0002-3258-3653
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-9012-6982
Ellen L GoodeDepartment of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9094-8326
Stephen B GruberDepartment of Medical Oncology and Therapeutics Research and Center for Precision Medicine, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-8656-7822
Andrea GsurCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-5472-6761
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8307-3197
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-8168-4712
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-4440-3368
Victor MorenoUnit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487
Neil MurphyNutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0003-3347-8249
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-8786-0043
Christina C NewtonDepartment of Population Science, American Cancer Society, Atlanta, Georgia.ORCID 0000-0003-1471-5608
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0943-7407
Mireia Obón-SantacanaUnit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0003-4646-3513
Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3909-2323
Wei SunPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-6350-1107
Amanda E TolandDepartments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-0271-1792
Quang M TrinhOntario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0002-3602-2290
Tomotaka UgaiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.ORCID 0000-0003-0182-5269
Syed H ZaidiOntario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0001-9964-8285
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-5666-9318
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-1446-2201
Fred Hutch Cancer Center · USUniversity of Washington · USBroad Institute · USThe University of Melbourne · AUAmerican Cancer Society · USBellvitge University Hospital · ESCentre international de recherche sur le cancer · FRHarvard University · USMayo Clinic · USNational Cancer Institute · USOntario Institute for Cancer Research · CAAlbert Einstein College of Medicine · USBrigham and Women's Hospital · USCancer Council Victoria · AUCedars-Sinai Medical Center · USCity Of Hope National Medical Center · USComprehensive Cancer Center Vienna · ATGerman Cancer Research Center · DEImperial College London · GBMassachusetts General Hospital · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI GIOVANNUCCI, EDWARD · 1991 to 2009
$41.8M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Molecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Detection of Colorectal Cancer Susceptibility Loci Using Genome-Wide SequencingU01CA164930 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2012 to 2015
$12.4M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
backgroundThe genotoxin colibactin causes a tumor single-base substitution (SBS) mutational signature, SBS88. It is unknown whether epidemiologic factors' association with colorectal cancer risk and survival differs by SBS88.
methodsWithin the Genetic Epidemiology of Colorectal Cancer Consortium and Colon Cancer Family Registry, we measured SBS88 in 4,308 microsatellite stable/microsatellite instability low tumors. Associations of epidemiologic factors with colorectal cancer risk by SBS88 were assessed using multinomial regression (N = 4,308 cases, 14,192 controls; cohort-only cases N = 1,911), and with colorectal cancer-specific survival using Cox proportional hazards regression (N = 3,465 cases).
results392 (9%) tumors were SBS88 positive. Among all cases, the highest quartile of fruit intake was associated with lower risk of SBS88-positive colorectal cancer than SBS88-negative colorectal cancer [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.37-0.76; OR = 0.75, 95% CI 0.66-0.85, respectively, Pheterogeneity = 0.047]. Among cohort studies, associations of body mass index (BMI), alcohol, and fruit intake with colorectal cancer risk differed by SBS88. BMI ≥30 kg/m2 was associated with worse colorectal cancer-specific survival among those SBS88-positive [hazard ratio (HR) = 3.40, 95% CI 1.47-7.84], but not among those SBS88-negative (HR = 0.97, 95% CI 0.78-1.21, Pheterogeneity = 0.066).
conclusionsMost epidemiologic factors did not differ by SBS88 for colorectal cancer risk or survival. Higher BMI may be associated with worse colorectal cancer-specific survival among those SBS88-positive; however, validation is needed in samples with whole-genome or whole-exome sequencing available. IMPACT: This study highlights the importance of identification of tumor phenotypes related to colorectal cancer and understanding potential heterogeneity for risk and survival.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature. · full record | OpenQuestion